Literature DB >> 9219490

Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel.

A F Schatzberg1, P Haddad, E M Kaplan, M Lejoyeux, J F Rosenbaum, A H Young, J Zajecka.   

Abstract

Although the number of documented serotonin reuptake inhibitor (SRI) discontinuation reactions is increasing, to date no systematic studies have been completed; therefore the mechanism of action for these reactions is not clearly understood. However, several hypotheses have been proposed. Researchers have postulated that discontinuation events result from a sudden decrease in the availability of synaptic serotonin in the face of down-regulated serotonin receptors. In addition, other neurotransmitters, such as dopamine, norepinephrine, or gamma-aminobutyric acid (GABA), may also be involved, although little research in this area has been published. Individual patient sensitivity, i.e., genetics or cognitive mindset, may also be a factor in SRI discontinuation phenomena. Finally, experts have hypothesized that since some symptoms associated with paroxetine withdrawal are similar to those of tricyclic antidepressant discontinuation, they may be caused by cholinergic rebound.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219490

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  11 in total

1.  Mirtazapine-Associated Withdrawal Symptoms: A Case Report.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-06

Review 2.  Use of antidepressants in older patients with co-morbid medical conditions: guidance from studies of depression in somatic illness.

Authors:  Gary J Kennedy; Paula Marcus
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.

Authors:  E C G van Geffen; J G Hugtenburg; E R Heerdink; R P van Hulten; A C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2005-05-20       Impact factor: 2.953

4.  Psychopharmacology of maternal separation anxiety in vervet monkeys.

Authors:  Lelanie Marais; Willie Daniels; Linda Brand; Francois Viljoen; Charmaine Hugo; Dan J Stein
Journal:  Metab Brain Dis       Date:  2006-07-19       Impact factor: 3.584

Review 5.  Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Authors:  K Black; C Shea; S Dursun; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

6.  A case report of onset of tinnitus following discontinuation of antidepressant and a review of the literature.

Authors:  Jane Clewes
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-16

7.  Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.

Authors:  Richard C. Shelton
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-08

8.  Bupropion-Associated Withdrawal Symptoms: A Case Report.

Authors:  Timothy R. Berigan; Jeffrey S. Harazin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-04

Review 9.  A review of the management of antidepressant discontinuation symptoms.

Authors:  Emma Wilson; Malcolm Lader
Journal:  Ther Adv Psychopharmacol       Date:  2015-12

10.  Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?

Authors:  Fumihiko Okada
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.